Summit Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jul '26 Jul 21, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Market Cap	10,890	13,561	13,167	1,831	897	264
Market Cap Growth	-48.13%	3.00%	618.96%	104.13%	240.18%	-32.05%
Enterprise Value	9,900	12,869	12,762	1,751	1,067	194.72
Last Close Price	14.03	17.49	17.85	2.61	4.25	2.69
PB Ratio	19.19	20.58	33.87	23.57	7.08	3.17
P/TBV Ratio	19.52	19.91	33.15	21.34	6.58	5.00
EV/EBITDA Ratio	-	11.76	65.09	-	-	-
EV/EBIT Ratio	-	11.76	65.11	-	-	-
Debt / Equity Ratio	0.03	0.03	0.01	1.33	4.08	0.02
Debt / EBITDA Ratio	0.02	0.02	0.04	-	-	-
Net Debt / Equity Ratio	-1.06	-1.05	-1.04	-1.03	1.34	-0.83
Net Debt / EBITDA Ratio	-0.47	-0.63	-2.07	0.19	-2.40	0.82
Net Debt / FCF Ratio	1.51	2.14	2.85	1.04	-4.03	0.95
Quick Ratio	7.19	9.77	9.89	9.17	9.15	3.47
Current Ratio	7.41	9.87	10.15	9.30	16.93	3.80
Return on Equity (ROE)	174.31%	-206.10%	-94.90%	-601.85%	-75.05%	-108.89%
Return on Assets (ROA)	174.80%	184.44%	61.39%	-99.68%	-18.54%	-79.85%
Return on Invested Capital (ROIC)	-	-	-	-293.64%	-46.35%	-620.58%
Return on Capital Employed (ROCE)	196.78%	204.18%	68.01%	-106.98%	-20.22%	-101.18%
Buyback Yield / Dilution	-4.04%	-4.06%	-15.96%	-220.50%	-46.78%	-89.45%
Total Shareholder Return	-4.04%	-4.06%	-15.96%	-220.50%	-46.78%	-89.45%

SEC Filings: 10-K · 10-Q